Who are Dapagliflozin / metFORMIN Pill's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dapagliflozin/Metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapagliflozin-metformin-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dapagliflozin / metFORMIN Pill — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dapagliflozin / metFORMIN Pill (Dapagliflozin / metFORMIN Pill) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor / Biguanide combination. Area: Diabetes.

marketed SGLT2 inhibitor / Biguanide combination SGLT2 (sodium-glucose cotransporter 2) / AMPK (AMP-activated protein kinase) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Dapagliflozin / metFORMIN Pill (Dapagliflozin / metFORMIN Pill) — Tan Tock Seng Hospital. Dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dapagliflozin / metFORMIN Pill TARGET	Dapagliflozin / metFORMIN Pill	Tan Tock Seng Hospital	marketed	SGLT2 inhibitor / Biguanide combination	SGLT2 (sodium-glucose cotransporter 2) / AMPK (AMP-activated protein kinase)
Dapagliflozin/Metformin	Dapagliflozin/Metformin	AstraZeneca	phase 3	SGLT2 inhibitor / Biguanide combination	SGLT2 (sodium-glucose cotransporter 2) / AMPK pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor / Biguanide combination class)

AstraZeneca · 1 drug in this class
Tan Tock Seng Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapagliflozin / metFORMIN Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-metformin-pill. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab